“Dupilumab met its safety endpoints and significantly outperformed placebo for adults with moderate to severe atopic dermatitis, according to final results of a multicenter, international phase IIb study.” according to edermatolygynews.com.
It’s exciting to hear about a new drug on the horizon for adults, however, I wish there was more effort on the children side as well. I rarely see any new drugs or therapies for eczema on children, when I believe this group has the highest rate of severe eczema on SCORAD.
A question that comes to mind if whether or not this drug will be covered by insurance providers. Although eczema therapies and treatment options are expensive as is, this drug will carry its own cost it seems. “Using the plaque-psoriasis market as a benchmark because of its similar size, Leerink estimated that a year of treatment would be priced between $15,000 and $20,000,” according to www.mmm-online.com/sanofiregeneron-eczema-drug-could-have-limited-competition/article/413289/
This article also mentions the limited competition aspect of this drug, which to me is more worrisome, because the last thing this industry needs is less competition. A competitive environment fosters new ideas, solutions to problems.
Sanofi is expected to file dupilumab with the FDA for atopic dermatitis by the fourth quarter of 2016.
Eczema Future & Research
February 24, 2016
